{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:44:58Z","timestamp":1785714298006,"version":"3.56.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Microbiome"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cystic fibrosis (CF) has profoundly changed since the introduction of CF Transmembrane Conductance Regulator modulator therapies (CFTRmt), a class of medications that improve function of the CFTR protein encoded by certain CF-causing gene mutations. Amongst these, the triple combination therapy elexacaftor\u2013tezacaftor\u2013ivacaftor (ETI) has been the most impactful and widely used to date. Given chronic respiratory infection and concomitant inflammation is the leading cause of morbidity and early mortality for the majority in CF, what is not certain are the long-term effects of ETI therapy on the respiratory microbiota and pathogens embedded within. Here, we assessed the effects of ETI CFTRmt over 3\u00a0years on the respiratory microbiota, using sputum and cough swab samples, from a multi-centre cohort of 276 adults with CF (awCF) from 6 CF centres in the UK, USA, and Canada, and compared to a non-CF healthy cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Using Kruskal\u2013Wallis analyses with post hoc Dunn\u2019s tests, Wilcoxon signed-rank tests, and PERMANOVA analyses with Bonferroni correction, we determined that respiratory microbiota characteristics (diversity, dominance, and composition) became decreasingly like those of awCF pre-ETI and remodelled to align more with the healthy cohort, where canonical CF pathogens increasingly became less ecologically important in terms of their distributions and abundances across awCF with increased duration on therapy. However, the on-ETI microbiota was impeded from becoming fully \u2018healthy\u2019 due to continued antibiotic exposure and irreversible lung damage experienced by awCF. Specifically, we found that azithromycin, an antibiotic widely used principally for its immunomodulatory benefits, was associated with adverse effects on the respiratory microbiota nullifying the observed positive effects of ETI treatment. Our results indicated that when administered alongside ETI therapy, azithromycin contributed to a pre-ETI microbiota dysbiosis and enabled enhanced persistence of emblematic CF pathogens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The highly anticipated introduction of ETI CFTRmt has greatly changed the course of CF for many people living with this inherited disease. Here, we find that ETI CFTRmt enabled positive remodelling of the respiratory microbiota towards a healthy-like state. However, azithromycin appeared to impede total remodelling, making it an ideal candidate for evaluation for discontinuation in the CFTRmt era. While traditional pathogens become less ecologically important, the potential evolution and emergence of virulent strains should be investigated. Additionally, the impacts and implications of ETI therapy on the understudied fungal microbiota should also be explored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40168-026-02440-7","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:43:37Z","timestamp":1780112617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor\u2013tezacaftor\u2013ivacaftor therapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Helen","family":"Gavillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren R.","family":"Hatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hardman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisli G.","family":"Einarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina S.","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Parkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Duckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Bomberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Hilliam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Horsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W. V.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte C.","family":"Teneback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian W.","family":"Rivett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"van der Gast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"2440_CR1","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn JS. Cystic fibrosis. Lancet. 2016;388:2519\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(16)00576-6.","journal-title":"Lancet"},{"issue":"4","key":"2440_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.paed.2019.01.011","volume":"29","author":"IJ Haq","year":"2019","unstructured":"Haq IJ, Parameswaran MC, Abidin NZ, Socas A, Gonzalez-Ciscar A, Gardner AI, et al. Modulator therapies for cystic fibrosis. Paediatr Child Health. 2019;29(4):151\u20137. https:\/\/doi.org\/10.1016\/j.paed.2019.01.011.","journal-title":"Paediatr Child Health"},{"key":"2440_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-025-02143-5","volume":"13","author":"L Cuthbertson","year":"2025","unstructured":"Cuthbertson L, Hatfield L, Gavillet H, Hardman M, Marsh R, Rivett DW, et al. Species turnover within cystic fibrosis lung microbiota is indicative of acute pulmonary exacerbation onset. Microbiome. 2025;13:140. https:\/\/doi.org\/10.1186\/s40168-025-02143-5.","journal-title":"Microbiome"},{"key":"2440_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-020-00810-3","volume":"8","author":"L Cuthbertson","year":"2020","unstructured":"Cuthbertson L, Walker AW, Oliver AE, Rogers GB, Rivett DW, Hampton TH, et al. Lung function and microbiota diversity in cystic fibrosis. Microbiome. 2020;8:45. https:\/\/doi.org\/10.1186\/s40168-020-00810-3.","journal-title":"Microbiome"},{"key":"2440_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-024-01780-6","volume":"12","author":"H Gavillet","year":"2024","unstructured":"Gavillet H, Hatfield L, Jones A, Maitra A, Horsley A, Rivett D, et al. Ecological patterns and processes of temporal turnover within lung infection microbiota. Microbiome. 2024;12:63. https:\/\/doi.org\/10.1186\/s40168-024-01780-6.","journal-title":"Microbiome"},{"key":"2440_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01456-24","volume":"16","author":"DW Rivett","year":"2024","unstructured":"Rivett DW, Hatfield LR, Gavillet H, Hardman M, van der Gast C. Bacterial interactions underpin worsening lung function in cystic fibrosis-associated infections. MBio. 2024;16:e01456-24. https:\/\/doi.org\/10.1128\/mbio.01456-24.","journal-title":"MBio"},{"key":"2440_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/ismej.2010.175","volume":"5","author":"CJ van der Gast","year":"2011","unstructured":"van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Scott P, Daniels TW, et al. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J. 2011;5:780\u201391. https:\/\/doi.org\/10.1038\/ismej.2010.175.","journal-title":"ISME J"},{"key":"2440_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100690","volume":"32","author":"S Sutharsan","year":"2023","unstructured":"Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F, Burkhart M, et al. Impact of Elexacaftor\/Tezacaftor\/Ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry. Lancet Reg Health Eur. 2023;32:100690. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100690.","journal-title":"Lancet Reg Health Eur"},{"key":"2440_CR9","unstructured":"UK Cystic Fibrosis Registry 2023 Annual Data Report. In. London, UK: Cystic Fibrosis Trust; 2024."},{"key":"2440_CR10","unstructured":"Cystic Fibrosis Foundation Patient Registry 2023 Annual Data Report. In. Bethesda, Maryland, USA: Cystic Fibrosis Foundation; 2024."},{"key":"2440_CR11","unstructured":"The Canadian Cystic Fibrosis Registry 2023 Annual Data Report. In. Toronto, Canada: Cystic Fibrosis Canada; 2024."},{"key":"2440_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00519-24","volume":"15","author":"CR Armbruster","year":"2024","unstructured":"Armbruster CR, Hilliam YK, Zemke AC, Atteih S, Marshall CW, Moore J, et al. Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis. MBio. 2024;15:e00519-24. https:\/\/doi.org\/10.1128\/mbio.00519-24.","journal-title":"MBio"},{"key":"2440_CR13","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00787-24","volume":"12","author":"Y Hilliam","year":"2024","unstructured":"Hilliam Y, Armbruster CR, Rapsinski GJ, Marshall CW, Moore J, Koirala J, et al. Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of Elexacaftor\/Tezacaftor\/Ivacaftor therapy. Microbiol Spectr. 2024;12:e00787-24. https:\/\/doi.org\/10.1128\/spectrum.00787-24.","journal-title":"Microbiol Spectr"},{"key":"2440_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02630-z","volume":"24","author":"C Martin","year":"2023","unstructured":"Martin C, Guzior DV, Gonzalez CT, Okros M, Mielke J, Padillo L, et al. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor\u2013Tezacaftor\u2013Ivacaftor therapy. Respir Res. 2023;24:317. https:\/\/doi.org\/10.1186\/s12931-023-02630-z.","journal-title":"Respir Res"},{"key":"2440_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167957","volume":"133","author":"DP Nichols","year":"2023","unstructured":"Nichols DP, Morgan SJ, Skalland M, Vo AT, Van Dalfsen JM, Singh SBP, et al. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist. J Clin Invest. 2023;133:e167957. https:\/\/doi.org\/10.1172\/JCI167957.","journal-title":"J Clin Invest"},{"key":"2440_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01454-22","volume":"10","author":"ST Pallenberg","year":"2022","unstructured":"Pallenberg ST, Pust M-M, Rosenboom I, Hansen G, Wiehlmann L, Dittrich A-M, et al. Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on the cystic fibrosis airway microbial metagenome. Microbiol Spectr. 2022;10:e01454-22. https:\/\/doi.org\/10.1128\/spectrum.01454-22.","journal-title":"Microbiol Spectr"},{"key":"2440_CR17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02153-2022","volume":"62","author":"L Schaupp","year":"2023","unstructured":"Schaupp L, Addante A, V\u00f6ller M, Fentker K, Kuppe A, Bardua M, et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir J. 2023;62:2202153. https:\/\/doi.org\/10.1183\/13993003.02153-2022.","journal-title":"Eur Respir J"},{"key":"2440_CR18","doi-asserted-by":"publisher","unstructured":"Sosinski LM, H CM, Neugebauer KA, Ghuneim L-AJ, Guzior DV, Castillo-Bahena A, et al. A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung. J Cyst Fibros. 2022;21:996\u20131005. https:\/\/doi.org\/10.1016\/j.jcf.2021.11.003.","DOI":"10.1016\/j.jcf.2021.11.003"},{"key":"2440_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2024.10.001","author":"R Steinberg","year":"2024","unstructured":"Steinberg R, Moeller A, Gisler A, Mostacci N, Hilty M, Usemann J. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on the oropharyngeal metagenome in adolescents with cystic fibrosis. J Cyst Fibros. 2024. https:\/\/doi.org\/10.1016\/j.jcf.2024.10.001.","journal-title":"J Cyst Fibros"},{"key":"2440_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/alr.23288","volume":"14","author":"AC Zemke","year":"2024","unstructured":"Zemke AC, Hilliam Y, Stapleton AL, Kimple AJ, Goralski JL, Shaffer AD, et al. Elexacaftor\u2013tezacaftor\u2013ivacaftor decreases Pseudomonas abundance in the sinonasal microbiome in cystic fibrosis. Int Forum Allergy Rhinol. 2024;14:928\u201338. https:\/\/doi.org\/10.1002\/alr.23288.","journal-title":"Int Forum Allergy Rhinol"},{"issue":"1","key":"2440_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64218-z","volume":"16","author":"RL Knoll","year":"2025","unstructured":"Knoll RL, Brauny MM, Robert E, Cloos L, Waser L, Hilbert K, et al. CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF Phase IV trial. Nat Commun. 2025;16(1):10111. https:\/\/doi.org\/10.1038\/s41467-025-64218-z.","journal-title":"Nat Commun"},{"key":"2440_CR22","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0068-2024","volume":"33","author":"J Milczewska","year":"2024","unstructured":"Milczewska J, Syunyaeva Z, \u017babi\u0144ska-Jaro\u0144 A, Sands D, Thee S. Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy. Eur Respir Rev. 2024;33:240068. https:\/\/doi.org\/10.1183\/16000617.0068-2024.","journal-title":"Eur Respir Rev"},{"key":"2440_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00419-22","volume":"10","author":"H Gavillet","year":"2022","unstructured":"Gavillet H, Hatfield L, Rivett D, Jones A, Maitra A, Horsley A, et al. Bacterial culture underestimates lung pathogen detection and infection status in cystic fibrosis. Microbiol Spectr. 2022;10:e00419-22. https:\/\/doi.org\/10.1128\/spectrum.00419-22.","journal-title":"Microbiol Spectr"},{"key":"2440_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.107002","volume":"204","author":"RE Maher","year":"2022","unstructured":"Maher RE, Barrett E, Beynon RJ, Harman VM, Jones AM, McNamara PS, et al. The relationship between lung disease severity and the sputum proteome in cystic fibrosis. Respir Med. 2022;204:107002. https:\/\/doi.org\/10.1016\/j.rmed.2022.107002.","journal-title":"Respir Med"},{"key":"2440_CR25","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1128\/jcm.00764-14","volume":"52","author":"L Cuthbertson","year":"2014","unstructured":"Cuthbertson L, Rogers GB, Walker AW, Oliver A, Hafiz T, Hoffman LR, et al. Time between collection and storage significantly influences bacterial sequence composition in sputum samples from cystic fibrosis respiratory infections. J Clin Microbiol. 2014;52:3011\u20136. https:\/\/doi.org\/10.1128\/jcm.00764-14.","journal-title":"J Clin Microbiol"},{"key":"2440_CR26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jcf.2014.10.004","volume":"14","author":"L Cuthbertson","year":"2015","unstructured":"Cuthbertson L, Rogers GB, Walker AW, Oliver A, Hoffman LR, Carroll MP, et al. Implications of multiple freeze-thawing on respiratory samples for culture-independent analyses. J Cyst Fibros. 2015;14:464\u20137. https:\/\/doi.org\/10.1016\/j.jcf.2014.10.004.","journal-title":"J Cyst Fibros"},{"key":"2440_CR27","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1128\/jcm.41.8.3548-3558.2003","volume":"41","author":"GB Rogers","year":"2003","unstructured":"Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol. 2003;41:3548\u201358. https:\/\/doi.org\/10.1128\/jcm.41.8.3548-3558.2003.","journal-title":"J Clin Microbiol"},{"key":"2440_CR28","unstructured":"Earth Microbiome Project. https:\/\/earthmicrobiome.org\/protocols-and-standards\/16s\/. Accessed 26 June 2025."},{"key":"2440_CR29","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jcf.2023.03.008","volume":"22","author":"L Hatfield","year":"2023","unstructured":"Hatfield L, Bianco B, Gavillet H, Burns P, Rivett D, Smith M, et al. Effects of postage on recovery of pathogens from cystic fibrosis sputum samples. J Cyst Fibros. 2023;22:816\u201322. https:\/\/doi.org\/10.1016\/j.jcf.2023.03.008.","journal-title":"J Cyst Fibros"},{"key":"2440_CR30","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jcf.2021.11.014","volume":"21","author":"R Marsh","year":"2022","unstructured":"Marsh R, Gavillet H, Hanson L, Ng C, Mitchell-Whyte M, Major G, et al. Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis. J Cyst Fibros. 2022;21:506\u201313. https:\/\/doi.org\/10.1016\/j.jcf.2021.11.014.","journal-title":"J Cyst Fibros"},{"key":"2440_CR31","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/bioinformatics\/btz848","volume":"36","author":"P-A Chaumeil","year":"2020","unstructured":"Chaumeil P-A, Mussig AJ, Hugenholtz P, Parks DH. GTDB-Tk: a toolkit to classify genomes with the Genome Taxonomy Database. Bioinformatics. 2020;36:1925\u20137. https:\/\/doi.org\/10.1093\/bioinformatics\/btz848.","journal-title":"Bioinformatics"},{"issue":"3","key":"2440_CR32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/s0022-2836(05)80360-2","volume":"215","author":"SF Altschul","year":"1990","unstructured":"Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215(3):403\u201310. https:\/\/doi.org\/10.1016\/s0022-2836(05)80360-2.","journal-title":"J Mol Biol"},{"key":"2440_CR33","volume-title":"Measuring biological diversity","author":"AE Magurran","year":"2004","unstructured":"Magurran AE. Measuring biological diversity. Oxford, UK: Blackwell Publishing; 2004."},{"key":"2440_CR34","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511623387","volume-title":"Species diversity in space and time","author":"ML Rosenzweig","year":"1995","unstructured":"Rosenzweig ML. Species diversity in space and time. Cambridge, UK: Cambridge University Press; 1995."},{"key":"2440_CR35","first-page":"4","volume":"4","author":"\u00d8 Hammer","year":"2001","unstructured":"Hammer \u00d8, Harper DAT, Ryan PD. PAST: paleontological statistics software package for education and data analysis. Palaeontol Electron. 2001;4:4.","journal-title":"Palaeontol Electron"},{"issue":"6933","key":"2440_CR36","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nature01547","volume":"422","author":"AE Magurran","year":"2003","unstructured":"Magurran AE, Henderson PA. Explaining the excess of rare species in natural species abundance distributions. Nature. 2003;422(6933):714\u20136. https:\/\/doi.org\/10.1038\/nature01547.","journal-title":"Nature"},{"key":"2440_CR37","volume-title":"CANOCO reference manual and user\u2019s guide: software for ordination, version 5","author":"CJF ter Braak","year":"2012","unstructured":"ter Braak CJF, Smilauer P. CANOCO reference manual and user\u2019s guide: software for ordination, version 5. Ithaca, USA: Microcomputer Power; 2012."},{"key":"2440_CR38","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1890\/0012-9658(2006)87[2614:vposdm]2.0.co;2","volume":"87","author":"PR Peres-Neto","year":"2006","unstructured":"Peres-Neto PR, Legendre P, Dray S, Borcard D. Variation partitioning of species data matrices: estimation and comparison of fractions. Ecology. 2006;87:2614\u201325. https:\/\/doi.org\/10.1890\/0012-9658(2006)87[2614:vposdm]2.0.co;2.","journal-title":"Ecology"},{"key":"2440_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36244-2","volume":"14","author":"L Allen","year":"2023","unstructured":"Allen L, Allen L, Carr SB, Davies G, Downey D, Egan M, et al. Future therapies for cystic fibrosis. Nat Commun. 2023;14:693. https:\/\/doi.org\/10.1038\/s41467-023-36244-2.","journal-title":"Nat Commun"},{"key":"2440_CR40","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nrmicro1643","volume":"5","author":"JI Prosser","year":"2007","unstructured":"Prosser JI, Bohannan BJM, Curtis TP, Ellis RJ, Firestone MK, Freckleton RP, et al. The role of ecological theory in microbial ecology. Nat Rev Microbiol. 2007;5:384\u201392. https:\/\/doi.org\/10.1038\/nrmicro1643.","journal-title":"Nat Rev Microbiol"},{"key":"2440_CR41","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1513\/AnnalsATS.201801-012OC","volume":"15","author":"JD Cogen","year":"2018","unstructured":"Cogen JD, Onchiri F, Emerson J, Gibson RL, Hoffman LR, Nichols DP, et al. Chronic azithromycin use in cystic fibrosis and risk of treatment-emergent respiratory pathogens. Ann Am Thorac Soc. 2018;15:702\u20139. https:\/\/doi.org\/10.1513\/AnnalsATS.201801-012OC.","journal-title":"Ann Am Thorac Soc"},{"key":"2440_CR42","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00502-2024","volume":"10","author":"S Bani Melhim","year":"2024","unstructured":"Bani Melhim S, Douglas LEJ, Reihill JA, Downey DG, Martin SL. The effect of triple CFTR modulator therapy and azithromycin on ion channels and inflammation in cystic fibrosis. ERJ Open Res. 2024;10:00502-2024. https:\/\/doi.org\/10.1183\/23120541.00502-2024.","journal-title":"ERJ Open Res"},{"key":"2440_CR43","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/aac.02067-13","volume":"58","author":"H Li","year":"2014","unstructured":"Li H, Liu D-H, Chen L-L, Zhao Q, Yu Y-Z, Ding J-J, et al. Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases. Antimicrob Agents Chemother. 2014;58:511\u20137. https:\/\/doi.org\/10.1128\/aac.02067-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"2440_CR44","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1513\/AnnalsATS.201310-352OC","volume":"11","author":"JA Nick","year":"2014","unstructured":"Nick JA, Moskowitz SM, Chmiel JF, Forss\u00e9n AV, Kim SH, Saavedra MT, et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc. 2014;11:342\u201350. https:\/\/doi.org\/10.1513\/AnnalsATS.201310-352OC.","journal-title":"Ann Am Thorac Soc"},{"key":"2440_CR45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/thx.2005.057950","volume":"61","author":"A Clement","year":"2006","unstructured":"Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax. 2006;61:895\u2013902. https:\/\/doi.org\/10.1136\/thx.2005.057950.","journal-title":"Thorax"},{"issue":"1","key":"2440_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-023-03073-8","volume":"23","author":"BD Wagner","year":"2023","unstructured":"Wagner BD, Zemanick ET, Sagel SD, Robertson CE, Stevens MJ, Mayer-Hamblett N, et al. Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early Pseudomonas infection. BMC Microbiol. 2023;23(1):312. https:\/\/doi.org\/10.1186\/s12866-023-03073-8.","journal-title":"BMC Microbiol"},{"key":"2440_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2025.107628","volume":"205","author":"W Wang","year":"2025","unstructured":"Wang W, Chen Y, Rasic M, Ascoli C, Hatch JE, Nemsick NK, et al. An observational study of the lung microbiome and lung function in young children with cystic fibrosis across two countries with differing antibiotic practices. Microb Pathog. 2025;205:107628. https:\/\/doi.org\/10.1016\/j.micpath.2025.107628.","journal-title":"Microb Pathog"},{"issue":"1","key":"2440_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-021-02159-5","volume":"21","author":"N Acosta","year":"2021","unstructured":"Acosta N, Thornton CS, Surette MG, Somayaji R, Rossi L, Rabin HR, et al. Azithromycin and the microbiota of cystic fibrosis sputum. BMC Microbiol. 2021;21(1):96. https:\/\/doi.org\/10.1186\/s12866-021-02159-5.","journal-title":"BMC Microbiol"},{"key":"2440_CR49","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jcf.2024.02.003","volume":"23","author":"SH Donaldson","year":"2024","unstructured":"Donaldson SH, Corcoran TE, Pilewski JM, Laube BL, Mogayzel P, Ceppe A, et al. The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor\/tezacaftor\/ivacaftor treated people with cystic fibrosis: the SIMPLIFY-MCC study. J Cyst Fibros. 2024;23:457\u201360. https:\/\/doi.org\/10.1016\/j.jcf.2024.02.003.","journal-title":"J Cyst Fibros"},{"key":"2440_CR50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","volume":"11","author":"N Mayer-Hamblett","year":"2023","unstructured":"Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med. 2023;11:329\u201340. https:\/\/doi.org\/10.1016\/S2213-2600(22)00434-9.","journal-title":"Lancet Respir Med"},{"key":"2440_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00382-25","author":"M Hardman","year":"2025","unstructured":"Hardman M, Higgi S, Hanson L, Schutz K, Wargo MJ, Teneback CC, et al. Nontuberculous mycobacteria remodel lung microbiota in cystic fibrosis-associated respiratory infections. Microbiol Spectr. 2025. https:\/\/doi.org\/10.1128\/spectrum.00382-25.","journal-title":"Microbiol Spectr"},{"issue":"5","key":"2440_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jcf.2011.05.002","volume":"10","author":"FA Stressmann","year":"2011","unstructured":"Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TWV, Carroll MP, et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros. 2011;10(5):357\u201365. https:\/\/doi.org\/10.1016\/j.jcf.2011.05.002.","journal-title":"J Cyst Fibros"},{"key":"2440_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000821","author":"T Vagg","year":"2021","unstructured":"Vagg T, Shanthikumar S, Morrissy D, Chapman WW, Plant BJ, Ranganathan S. Telehealth and virtual health monitoring in cystic fibrosis. Curr Opin Pulm Med. 2021. https:\/\/doi.org\/10.1097\/MCP.0000000000000821.","journal-title":"Curr Opin Pulm Med"},{"key":"2440_CR54","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","volume":"22","author":"A Lopez","year":"2023","unstructured":"Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL. Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros. 2023;22:607\u201314. https:\/\/doi.org\/10.1016\/j.jcf.2023.02.004.","journal-title":"J Cyst Fibros"}],"container-title":["Microbiome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40168-026-02440-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40168-026-02440-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40168-026-02440-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:53:33Z","timestamp":1785711213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40168-026-02440-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2440"],"URL":"https:\/\/doi.org\/10.1186\/s40168-026-02440-7","relation":{},"ISSN":["2049-2618"],"issn-type":[{"value":"2049-2618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved for each participating centre: Burlington, VT, USA (University of Vermont Institutional Review Board, CHRMS STUDY683), Calgary, AB, Canada (University of Calgary\u2019s Conjoint Health Research Ethics Board, REB-15\u20132744), Cardiff, UK (Health and Care Research Wales Research Ethics Committee, 18\/WA\/0089), Manchester, UK (North West\n\u2013 Preston Research Ethics Committee, 20\/NW\/0302 and NHS Research Ethics Committee North West, Lancaster, 14\/NW\/1195), Pittsburgh, PA, USA (University of Pittsburgh Institutional Review Board, STUDY19100149), and Southampton, UK (South Central \u2013 Hampshire A Research Ethics Committee, 08\/H0602\/126). All patients attending each participating centre provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"192"}}